Tenax Therapeutics Confirms Cash Runway into 2027 Amid $52.6M Annual Loss
Summary
TENAX Therapeutics' 10-K filing reveals a net loss of $52.6 million and a net operating loss of $56.4 million for the year, primarily driven by increased R&D and G&A expenses as the company scales up its clinical activity. This follows earlier reports of a widened Q4 net loss. Crucially, the company reported $97.1 million in working capital, which management expects will fund operations through at least the end of 2027. This extended cash runway is a significant positive for a clinical-stage biotech, providing financial stability to complete its ongoing Phase 3 LEVEL and LEVEL-2 trials for levosimendan. Investors will closely monitor the progress of these pivotal clinical trials.
At the time of this announcement, TENX was trading at $10.69 on NASDAQ in the Life Sciences sector, with a market capitalization of approximately $68.8M. The 52-week trading range was $4.63 to $18.38. This news item was assessed with neutral market sentiment and an importance score of 8 out of 10. Source: Wiseek News.